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Abstract 
Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p’-DDD) is the most effective 
medical therapy for adrenocortical carcinoma but its molecular mechanism of action remains poorly 
understood. Although mitotane is known to have mitochondrial (mt) effects, a direct link to 
mitochondrial dysfunction has never been established. We examined the functional consequences on 
proliferation, steroidogenesis, and mitochondrial respiratory chain, biogenesis and morphology, of 
mitotane exposure in two human adrenocortical cell lines, the steroid-secreting H295R line and the 
non-secreting SW13 line. Mitotane inhibited cell proliferation in a dose- and a time-dependent 
manner. At the concentration 50µM (14 mg/L), which corresponds to the threshold for therapeutic 
efficacy, mitotane drastically reduced cortisol and 17-hydroxyprogesterone secretions by 70%. This 
was accompanied by significant decreases in the expression of genes encoding mitochondrial proteins 
involved in steroidogenesis (STAR, CYP11B1, CYP11B2). In both H295R and SW13 cells, 50µM 
mitotane significantly inhibited (50%) the maximum velocity of the activity of the respiratory chain 
complex IV (cytochrome c oxidase, COX). This effect was associated with a drastic reduction in 
steady-state levels of the whole COX complex as revealed by Blue Native PAGE and reduced mRNA 
expression of both mtDNA-encoded COX2 and nuclear DNA-encoded COX4 subunits. In contrast, 
the activity and expression of respiratory chain complexes II and III were unaffected by mitotane 
treatment. Lastly, mitotane exposure enhanced mitochondrial biogenesis (increase in mtDNA content 
and PGC1α expression) and triggered fragmentation of the mitochondrial network. Altogether, our 
results provide first evidence that mitotane induced a mitochondrial respiratory chain defect in human 
adrenocortical cells.  
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Introduction 
Adrenocortical carcinoma (ACC) is a rare disease affecting 2 patients per million people per year, 
representing less than 0.1% of all cancer cases. ACC prognosis is poor with less than 15% of patients 
surviving 5 years or more once metastases are diagnosed (Assie, et al. 2007; Fassnacht and Allolio 
2009; Icard, et al. 2001; Lughezzani, et al. 2010). 
Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p’-DDD) is a synthetic 
derivative of an insecticide. It acts selectively on the adrenal cortex where it has a cytotoxic effect and 
impairs steroidogenesis (Bergenstal and Dao 1953). Mitotane is a part of the reference treatment of 
advanced ACC (Berruti 2012; Fassnacht, et al. 2012). Indeed, it remains the single most effective 
drug, inducing a partial response in up to one third of the treated patients (Baudin, et al. 2011). Several 
retrospective studies have shown that plasma mitotane levels above 14 mg/L are associated with a 
higher partial response rate and improve overall survival (Baudin, et al. 2001; Haak, et al. 1994; 
Hermsen, et al. 2011; Malandrino, et al. ; Wangberg, et al.). The current recommendation to achieve 
optimal benefit over risk ratio in patients with unresectable ACC is to maintain plasma mitotane levels 
between 14 and 20 mg/L (Berruti 2012).  
Mitotane’s molecular mechanisms of action remain largely unknown, although mitochondrial effects 
have been reported. Kaminsky et al observed swollen mitochondria in the adrenal cortex of mitotane-
treated dogs by electron microscopy (Kaminsky, et al. 1962). Subsequently, Martz et al suggested that 
metabolic transformation of o,p’-DDD into the active metabolite o,p’-DDA occurs in mitochondria 
and is catalyzed by an unknown cytochrome P450 (Martz and Straw 1977). Mitotane metabolism 
seems to involve two successive reactions of β-hydroxylation and dehydrochlorination, leading to 
production of free radicals that could potentially result in apoptosis (Cai, et al. 1995). Critical steps of 
mitotane’s inhibitory effects on steroidogenesis may occur in mitochondria possibly involving 
CYP11A1, a mitochondrial enzyme that catalyzes the transformation of cholesterol to pregnenolone 
(Cai, et al. 1997). Elevated levels of 11-deoxycortisol and 11-deoxycorticosterone in mitotane-treated 
patients suggest that mitotane may affect CYP11B1, which is responsible for cortisol synthesis (Asp, 
et al.). More recently, Stigliano et al showed by proteomic analysis of H295R cells that expression of 
proteins involved in stress response, energy metabolism and tumorigenesis was greatly altered by 
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mitotane exposure (Stigliano, et al. 2008). Interestingly, some of these regulated proteins were 
mitochondrial components, even though a direct impact on their synthesis and/or stability has not been 
clearly demonstrated. The functional consequences of mitotane on respiratory chain expression and 
activity have not yet been examined. The respiratory chain consists of four multienzymatic complexes 
located in the mitochondrial inner membrane. Together with the ATP synthase complex, it performs 
an essential mitochondrial function, generating the vast majority of cellular ATP synthesis, while 
reducing molecular oxygen into water. It is a major source of free radicals in most cells and its 
function is tightly linked to apoptosis balance. The respiratory chain has been shown to be the target of 
several pharmacological compounds including non-steroidal anti-inflammatory drugs, antiretrovirals, 
and chemotherapy agents (Viengchareun, et al. 2007)
,
(Fedeles, et al. ; Scatena 2012). 
The aim of the present study was to evaluate the functional consequences of mitotane exposure on 
mitochondrial oxidative phosphorylation (OXPHOS) in human adrenocortical steroid-secreting 
H295R and non-secreting SW13 cells, both derived from human ACC. We used complementary 
experimental approaches including spectrophotometric assays, Western Blot, quantitative PCR, and 
mitochondrial morphological analysis to explore how mitotane affects mediators of steroidogenesis 
and respiratory chain activity.  
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Materials and methods 
 
Cell culture and treatment 
H295R and SW13 cells were cultured in Dulbecco’s modified Eagle’s medium/Ham’s medium 
(DMEM/HAM’S F-12, PAA, Les Mureaux, France) supplemented with 20 mM HEPES (Invitrogen, 
Life technologies, Saint Aubin, France), antibiotics (penicillin 100 IU/ml, streptomycin 100 µg/mL) 
and 2 mM glutamine. The medium for H295R cell culture was enriched with 10% fetal bovine serum 
and a mixture of insulin/transferrin/selenium. Both cell lines (from passage 2 to 15) were cultured at 
37°C in a humidified incubator with 5% CO2. Mitotane (supplied by HRA Pharma, Paris, France) 
dissolved in dimethyl sulfoxyde (DMSO) was added to cell cultures at final concentrations of 10 to 
100 µM; the therapeutic plasma mitotane level is 50 µM (14 mg/L). 
 
Cell proliferation analysis 
Cell proliferation was studied in Celltiter 96 assays (Promega, Madison, WI, USA) according to the 
manufacturer’s recommendations. Cells were cultured in 96-well plates and treated with 10 to 100 µM 
mitotane for 24, 48 or 72 h. Absorbance was measured by photometry (Viktor, Perkin Elmer, 
Courtaboeuf, France) 1 h after addition of 20 µL of Celltiter solution per well.  
 
Cortisol and 17-OH-progesterone secretion 
The cortisol and 17-hydroxyprogesterone concentrations in H295R culture supernatants were 
determined by radioimmunometric assays, using polyclonal antibodies (anti-cortisol: Orion 
Diagnostica, Spectria, Espoo, Finland; anti-17-hydroxyporgesterone: MP Biomedical, Solon, OH, 
USA). The intra- and inter-assay coefficients of variation of the cortisol were, respectively, 4.5% and 
5.5% at 22 µg/L and 4.2% and 4.3% at 269 µg/L, with a detection limit of 5 µg/l while those of the 17-
hydroxyprogesterone assay were 7.8% and 12% at 0.92 ng/mL and 8.3% and 9.8% at 4.3 ng/mL with 
a detection limit of 0.02 ng/mL. 
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Reverse Transcriptase-PCR (RT-PCR) and Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted from tissues or cells with the RNeasy kit (Qiagen, Courtaboeuf, France) 
according to the manufacturer’s recommendations. RNA was thereafter processed for RT-PCR as 
previously described (Martinerie, et al. 2011). Quantitative real-time PCR qRT-PCR was performed 
using the Fast SYBR
®
 Green Master Mix (ABI, Applied Biosystems, FosterCity, CA, USA) and 
carried out on a StepOnePlus™ Real-Time PCR System (Applied Biosystems) as previously described 
(Martinerie et al. 2011). Standards and samples were amplified in duplicate and analyzed from three 
independent experiments. The internal control for data normalization was the ribosomal 18S rRNA.  
The relative expression of each gene is expressed as the ratio of attomoles of the specific gene to 
femtomoles of 18S rRNA. The primer sequences of the genes analyzed by qRT-PCR are shown in the 
Supplemental Table. 
 
mtDNA quantification 
Mitochondrial DNA quantification was performed on total DNA extracted from tissues or cells using 
standard techniques. DNA was quantified by qPCR using the COX2 gene on the mtDNA as a target 
gene as previously described (Viengchareun et al. 2007). Results were expressed as relative expression 
of COX2 normalized with the nuclear 18S gene. 
 
Respiratory chain analysis 
Respiratory chain activities were measured using spectrophotometric assays. H295R and SW13 cells 
were treated with mitotane or vehicle (DMSO) alone for various periods of time, 24h, 48 h or 72 h and 
the activity of four mitochondrial respiratory complexes — complex I (NADH-ubiquinol 
oxidoreductase), complex II (succinate-ubiquinol oxidoreductase), complex III (ubiquinol-cytochrome 
c oxidoreductase), and complex IV (cytochrome c oxidase, or COX) — were measured in a Cary 50 
spectrophotometer (Rustin, et al. 1994). Assays of complexes II, III, and IV were performed on cell 
homogenates, and their activities normalized to citrate synthase activity, as an index of mitochondrial 
mass. Complex I assays were performed on purified mitochondrial fractions, prepared from 
permeabilized cells as previously described (Chretien, et al. 2003).  
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BN-PAGE analysis 
Mitochondria and oxidative phosphorylation (OXPHOS) complexes were isolated from cultured cells 
using 2% (W/V) digitonin and analysed as described (Nijtmans, et al. 2002a) (Nijtmans, et al. 2002b). 
Fifteen micrograms of solubilized OXPHOS proteins were loaded on a 4-16% gradient acrylamide 
non-denaturing gel (Invitrogen). After electrophoresis, proteins were transferred to a PVDF 
membrane. Immunoblotting was performed with monoclonal antibodies (Mitosciences, Mundolsheim, 
France) raised against the complex I GRIM19 subunit, the 70 kDa complex II subunit, the complex III 
subunit core2 and the complex IV subunit COX1. Peroxidase-conjugated anti-mouse IgG secondary 
antibodies were added and the signal was generated using enhanced chemiluminescence ECL (Pierce, 
Rockford, USA). Membranes were scanned using the Odyssey infrared imaging system and images 
were processed with the Image Studio Software (LI-COR Biosciences, Lincoln, NE, USA).  
 
Mitochondrial morphology 
Cells were seeded at subconfluence on a glass coverslip and incubated for 24-48 h in the presence or 
absence of 50 µM mitotane, briefly rinsed with warm PBS, then fixed in 3% paraformaldehyde in 
PBS. Mitochondria were labeled with antibodies against COX2 subunit as described (Agier, et al. 
2012). 
 
Statistical Analysis 
Results are expressed as means ± SEM of n independent replicates performed in the same experiment 
or from n separated experiments. Differences between groups were analyzed using non-parametric 
Kruskall Wallis ANOVA followed by Dunn’s multiple comparison test or non-parametric Mann 
Whitney test as appropriate. The significance level was p< 0.05. 
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Results 
 
Mitotane treatment reduces human adrenocortical H295R and SW13 cell proliferation 
Proliferation index was calculated using the colorimetric solution Celltiter 96. Exposure to mitotane 
for 48 h inhibited the proliferation of H295R and SW13 cells in a dose dependent manner, 100 µM 
o,p’-DDD significantly reducing the proliferation rate of H295R by 45% and that of  SW13 cells  by 
30% (Fig. 1A and 1B). The anti-proliferative effect of mitotane was also time-dependent, 100 µM 
mitotane inhibiting of H295R cells proliferation by 18% after 24 h and by 70% after 72 h. Subsequent 
experiments were performed using 50 µM mitotane to minimize the drug’s potential cytotoxic effects.  
 
Effect of mitotane on steroidogenesis in H295R cells 
To confirm the ability of mitotane to inhibit hormone secretion, we measured several steroid hormones 
concentrations in the culture supernatant of H295R cells. Exposure to 50 µM mitotane for 48 h 
significantly reduced the secretion of both cortisol and 17-OH-progesterone about 80% by H295R 
cells (Fig. 1C). Other steroid hormones such as aldosterone were undetectable in culture supernatants 
under these experimental conditions.  
To address the mechanisms underlying this decreased steroid secretion, we analyzed the expression of 
genes that encode mitochondrial effectors of steroidogenesis by qRT-PCR. Mitotane significantly 
decreased the expression of such genes: STAR, which encodes the Steroidogenic Acute Regulatory 
protein that transports cholesterol into mitochondria, the first rate limiting step for the 
intramitochondrial steroidogenic pathway (80% inhibition after 48 h, Fig. 2A); CYP11A (cholesterol 
desmolase), HSD3B2 (3 beta hydroxysteroid dehydrogenase); CYP11B1 (11β hydroxylase) which 
catalyzes 11-deoxycorticosterone and 11-deoxycortisol transformation into corticosterone and cortisol 
respectively (75% inhibition, Fig. 2B); and CYP11B2 (aldosterone synthase), the last intra-
mitochondrial enzymatic step in aldosterone synthesis (97%, inhibition, Fig. 2C). The mitotane-
induced inhibition of steroid secretion observed in H295R cells therefore appeared to be due to 
decreased expression of the steroidogenic enzymes. 
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Effect of Mitotane on the respiratory chain 
The impact of mitotane on respiratory chain activity was evaluated by spectrophotometric assays of 
the activities of the four mitochondrial respiratory complexes in H295R and SW13 cells treated with 
vehicle (DMSO) or 50 µM mitotane during 48 h (Table I). Citrate synthase activity, belonging to the 
mitochondrial citric acid cycle, was used as an index of the mitochondrial mass. Its activity was very 
high in H295R cells (299 ± 22 nmol/min/mg prot; n= 12) but lower in SW13 cells (159 ± 11 
nmol/min/mg prot; n= 8) suggesting that H295R cells have a greater mitochondrial population than 
SW13 cells consistent with their important steroidogenic capacity. However, citrate synthase activity 
was not affected by mitotane exposure (260 ± 31 nmol/min/mg prot in H295R and 135 ± 7 
nmol/min/mg prot in SW13 cells).  
Both H295R and SW13 mitotane-treated cells exhibited a significant cytochrome c oxidase (COX or 
complex IV) defect of approximately 50% after 48 h while complex II (succinate-ubiquinone 
oxidoreductase) appeared unaffected (Table I). Complex III (ubiquinol-cytochrome c oxidoreductase) 
activity remained unchanged in H295R cells and was slightly reduced in SW13 cells after mitotane 
treatment (Table I) but this decrease was not confirmed after normalization to citrate synthase activity 
(Table I). Complex I (NADH-ubiquinone oxidoreductase) activity can only be reliably measured on 
purified mitochondrial fractions due to the presence of numerous non-mitochondrial NADH oxidase 
activities in cell homogenates but its activity was greatly decreased after exposure to mitotane in both 
human adrenocortical cell lines after exposure to mitotane (Table I). Altogether, our results 
demonstrate that mitotane selectively inhibits some but not all respiratory chain complexes. 
The effect of mitotane on complex IV was concentration-dependent, as shown in Fig. 3, with an IC50 
calculated at approximately 67 µM mitotane (linear regression test; y=92.862-0.583x, r
2
= 0.97). This 
mitotane concentration corresponds to the therapeutic plasma threshold predictive of efficacy in 
clinical practice (Baudin et al. 2001; Haak et al. 1994). 
To examine whether o,p’-DDD might directly affect the enzymatic activity of complex IV, we 
measured cytochrome c oxidase activity on cell homogenates incubated with increasing concentrations 
of mitotane. Under these conditions, we demonstrated that mitotane dose-dependently decreased 
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complex IV activity with an IC50 of approximately 133 µM (linear regression test; y=100.2-0.3749x, 
r
2
= 0.96) (Fig. 4). This IC50 in the cell homogenate system is twice as high as the IC50 observed when 
whole cells were treated for 48 h indicating that mitotane exerts both direct and indirect inhibitory 
effects on cytochrome c oxidase activity. Our results strongly suggested that mitotane inhibits 
enzymatic activity directly but presumably inhibits the expression of the enzyme. We therefore studied 
the expression of cytochrome c oxidase at both the mRNA and protein level.  The cytochrome c 
oxidase complex consists of 13 subunits, three of which, including COX2, are encoded by the 
mitochondrial genome while the remaining 10 subunits, including COX4, are encoded by nuclear 
genes. We observed that the steady-state levels of mitochondrial and nuclear DNA-encoded COX2 
and COX4 transcripts in both H295R and SW13 cells were drastically decreased (by 70%) in H295R 
cells after exposure to 50 µM mitotane for 48 h (Fig. 5A and 5B). Similar results were obtained in 
SW13 cells (data not shown).  
We analyzed the whole respiratory chain complexes by Blue Native PolyAcrylamide Gel 
Electrophoresis (BN-PAGE). Immunoblotting with antibodies directed against a component of each 
mitochondrial complexes revealed that Mitotane exposure for 48 h induced a 45-70% decrease in the 
steady-state expression of complex IV and complex I proteins while the abundance of complexes II 
and III appeared unchanged (Fig. 5C and 5D). These data were fully consistent with the decreased 
enzymatic activities described above (Table I). Altogether, our results demonstrate that mitotane has 
deleterious consequences by acting at the mRNA and protein level to impair respiratory chain 
expression and function. 
To evaluate the possibility that mitotane has direct toxic effects on the mitochondrial DNA, we 
quantified mitochondrial DNA by qPCR. As illustrated on Fig. 6A, the mitochondrial/nuclear DNA 
ratio was unaffected  by exposure of low or moderate doses of mitotane for 48 h. However, this ratio 
increased significantly after treatment with 100 µM mitotane and with longer exposure times (e.g 50 
µM mitotane for 72 h), suggesting the presence of a compensatory response of mitochondrial 
biogenesis (Fig. 6B). To further explore this hypothesis, we quantified the expression of PGC1α 
(peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a transcriptional coactivator 
considered a key regulator of mitochondrial biogenesis. PGC1α mRNA expression was slightly but 
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significantly induced by 50 µM mitotane treatment for 48 h, suggesting activation of transcriptional 
response (Fig. 6C). Furthermore, no mtDNA mutations or deletions were found by sequencing 
mtDNA from mitotane-treated cells. 
 
Effect of mitotane on mitochondrial morphology 
Finally, to get an integrated evaluation of the mitotane-induced mitochondrial respiratory chain defect, 
we analyzed the mitochondrial morphology by immunocytochemistry using an antibody against 
COX2. Treatment with 50µM mitotane induced drastic morphological alterations in the mitochondria 
of adrenocortical cells. In the absences of treatment, the mitochondrial compartment appeared as a 
highly interconnected tubular network with a filamentous appearance after exposure do the drug but 
exhibited a more punctiform pattern, consistent with mitochondrial fragmentation (Fig. 7).  
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Discussion 
Even though combination of mitotane and cisplatin-based chemotherapy has been recently shown to 
clinically improve the overall survival in advanced adrenocortical carcinoma (Fassnacht et al. 2012), 
mitotane remains the single most active pharmacological option for the management of ACC, as 
recognized in recent recommendations (Berruti 2012). However, its mechanism of action still remains 
unclear. In the present study, we addressed the question on the mitochondrial effects of mitotane on 
two different human adrenocortical cell lines derived from human ACC aiming at identifying potential 
molecular targets of the drug. Attempts to perform similar experiments on primary human 
adrenocortical carcinoma cells have been so far unsuccessful. 
We found that at optimal therapeutic concentrations (50 µM i.e 4-20 mg/L), mitotane drastically 
altered mitochondrial function in both steroid-secreting and non-secreting adrenocortical cell lines 
derived for human ACC. Mitotane inhibited steroid hormone production and secretion which was 
accompanied by a reduction in steady-state mRNA levels of genes encoding mitochondrial proteins 
involved in steroidogenesis pathways. More importantly, we demonstrated for the first time that 
exposure to 50 µM mitotane significantly impairs the mitochondrial respiratory chain. Mitotane 
exposure also stimulated mitochondrial biogenesis and altered mitochondrial morphology in 
adrenocortical cells.  
It is well established that the in vivo anti-proliferative efficacy of mitotane depends on its circulating 
plasma level (Baudin et al. 2001). However, its pharmacokinetic profile with a unmet need for 
improved bioavailability and its metabolic conversion constitute potential limitations (Schteingart 
2007). It has been suggested that the metabolic transformation of o,p’-DDD is carried out in the 
adrenal mitochondria, the first enzymatic step being catalyzed by an unknown P450 cytochrome-
mediated hydroxylase leading to an adrenolytic effect (Cai et al. 1995; Martz and Straw 1977). In 
accordance to previous studies, we confirmed that mitotane inhibits steroidogenesis reducing cortisol 
and 17-hydroxyprogesterone secretions by 70% (Schteingart, et al. 1993; Stigliano et al. 2008). 
Mitotane exposure also decreased mRNA levels of STAR, the cholesterol carrier into the mitochondria, 
as well as CYP11A, CYP11B1 and CYP11B2, three mitochondrial enzymes involved in cortisol and 
aldosterone biosynthesis, respectively. However, the degree and extent of mitotane-induced repression 
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of genes involved in steroidogenesis seem to vary greatly between studies (Asp et al. ; Lin, et al. 2012; 
Zsippai, et al. 2012), supporting mitochondria as a main target of the drug’s action.  
 The mitotane transformation into active acylchlorine metabolites that takes place in the 
mitochondria of adrenal gland is believed to be responsible for cell toxicity and may explain the 
selective adrenolytic effect of the drug (Cai et al. 1995; Lindhe, et al. 2002). This hypothesis awaits 
further confirmation at the clinical level (Hermsen et al. 2011). At variance with the hepatic 
microsomal transformation of mitotane by CYP3A4 (Kroiss, et al. 2011; van Erp, et al. 2011), which 
is likely responsible for the pharmacokinetic interaction whereby mitotane reduces plasma levels of  
sunitinib (Fassnacht et al. 2012; Kroiss, et al. 2012), it has been suggested that CYPc11 or CYP11B1 
could be involved in tissue-specific and compartment-selective mitotane metabolism (Lindhe et al. 
2002; Lund and Lund 1995). Although CYP11B1 may catalyze the initial hydroxylation step of 
mitotane (Cai et al. 1995; Lindhe et al. 2002; Lund and Lund 1995), its direct involvement in 
mitochondrial dysfunction is very unlikely given that SW13 cells, which do no express CYP11B1, 
were similarly affected by mitotane treatment. In any case, the relationship between the potential 
hepatic metabolism of mitotane and its adrenal effect remains currently unknown. For instance, it 
remains to be established whether intra-mitochondrial transformation of mitotane into o,p’-DDA and 
o,p’-DDE compounds has deleterious consequences on OXPHOS. However, preliminary results from 
our laboratory reveal the presence of active mitotane uptake into H295R cells, suggesting that 
intracellular accumulation of mitotane and/or one of its metabolites may account for its cytotoxic 
effects. 
Given that most enzymatic steps of steroid hormone biosynthesis take place in the mitochondria and 
that mitotane inhibits steroidogenesis, we examined whether mitotane impedes mitochondrial 
respiratory chain function. Interestingly, in both H295R and SW13 cells, OXPHOS analyses indicated 
that mitotane induced a significant and selective decrease in the maximum velocity of COX activity, 
whereas complex II and III activities were unaltered. Mitotane has both direct and indirect inhibitory 
effects on COX: direct inhibition of the enzymatic activity was revealed in our experiments on cell 
homogenate incubation with o,p’-DDD but the drug also inhibited expression of the enzyme at both 
the mRNA and protein level. Inhibition of gene expression was observed for both the mtDNA-
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encoded COX2 and the nuclear DNA-encoded COX4 subunits. Immunobloting provided additional 
support for a reduction in steady-state COX protein expression. Concomitantly, normal activity and 
expression of respiratory chain complexes II and III or of citrate synthase, a Krebs cycle enzyme, 
suggest that mitotane caused selective enzymatic disruption rather than global mitochondrial damage, 
as initially proposed (Kaminsky et al. 1962). 
Herein, we confirm the adrenolytic effect of mitotane by showing that mitotane exposure leads to a 
time- and concentration-dependent reduction of adrenocortical cell numbers. Interestingly, this was 
accompanied by enhanced mitochondrial biogenesis, as demonstrated by increased mtDNA content 
and PGC1α expression, reminiscent of a cellular compensation mechanism in response to the 
respiratory chain defect. This adaptive pathway, combining increased mitochondrial mass, increased 
DNA copy level and impaired OXPHOS, has already been reported in mitochondrial myopathies 
caused by mtDNA mutations (Srivastava, et al. 2009). However, no mtDNA mutations or deletions 
were found by sequencing mtDNA from mitotane-treated cells. Of particular interest, mitotane 
exposure also triggered morphologic fragmentation of the mitochondrial network, which could be 
related to disequilibrium between mitochondrial fission and fusion (Chen and Chan 2010). It is well 
established that the integrity of mitochondrial outer and inner membranes is required for respiratory 
chain activity (Chen, et al. 2010; Liesa, et al. 2009) and presumably steroidogenesis (Duarte, et al. 
2012). It is not known however whether mitochondrial fragmentation has a direct relationship with or 
a causal role in genotoxic stress and apoptosis.  
In summary, our results show that mitotane alters mitochondrial respiratory chain activity in human 
adrenocortical cells, notably by inducing a cytochrome c oxidase defect. Further studies are needed to 
examine whether and how such mitotane-induced mitochondrial dysfunction translates into 
adrenolytic and antitumor effects on human ACC (Costa, et al. 2011).  
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Abbreviations: 
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Figure Legends: 
Figure 1 
Dose-dependent inhibition of the proliferation index of human adrenocortical H295R (A) and SW13 
(B) cells in response to increasing concentrations of mitotane (0  µM to 100 µM) after 48 h, as 
determined by Celltiter assay (See Material and Methods section). Results are expressed as the mean 
percentage ± SEM of 12 independent determinations of the expression measured in untreated cells, 
arbitrarily set at 100%. *p<0.05, ** p<0.01, Mann Whitney test. Proliferation was affected in a dose-
dependant manner in both cell lines. 
Inhibition of cortisol and 17 hydroxy-progesterone secretions by the steroid-secreting H295R cells 
(C). Cells were cultured with 50 µM of mitotane for 48 h, and the steroid concentrations were 
measured in the cell supernatants by Radioimmunometric assays. Results are means ± SEM of 4 
independent determinations and are expressed as percentage of secretion under basal conditions (mean 
cortisol and 17OHP secretions were 157 and 358ng/48 h/mg protein per well, respectively). Steroid 
hormone secretion was significantly inhibited by 80% after mitotane exposure. 
 
Figure 2 
Expression of genes encoding mitochondrial and cytoplasmic proteins involved in steroidogenesis. 
H295R cells were treated with 50 µM of mitotane for 48 h. Relative mRNA expression of STAR 
(Steroidogenic Acute Regulatory protein), CYP11A, HSD3B2, CYP11B1 and CYP11B2 was 
determined using qRT-PCR. Results, are means ± SEM of 4 different experiments performed in 
duplicate and are expressed as the percentage of the relative expression in DMSO-treated cells, 
arbitrarily set at 100%. Mitotane drastically inhibits gene expression ** p<0.01, *** p<0.001 Mann 
Whitney test.  
 
Figure 3 
Dose-dependent inhibition of Cytochrome c oxidase (Complex IV, COX) activity in H295R cells by 
mitotane. H295R cells were treated for 48 h with increasing concentrations of mitotane (0 µM to 100 
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µM) and the COX activity was measured by spectrophotometry as described in Materiel and methods 
section. Results are expressed as nmol/min/mg prot. Each point represents the mean of 3-6 
independent determinations. Mitotane inhibits Complex IV activity in a concentration-manner with a 
calculated IC50 at 58 µM.  
 
Figure 4 
Dose-dependent inhibition of cytochrome c oxidase (COX) activity by mitotane. COX activity was 
measured by spectrophotometry in cell homogenates of H295R cells incubated with increasing 
concentrations of mitotane (0 µM to 100 µM) for 48 h (black circles, living cell incubation) or in cell 
homogenates simultaneously exposed to increasing concentrations of mitotane (0 µM to 200 µM) 
immediately added before the enzymatic assay (Black squares homogenate incubation). Each 
experiment was repeated two to six times. Results are expressed as the percentage of control COX 
activity measured in the absence of mitotane arbitrary set at 100%. Mitotane directly inhibits Complex 
IV activity with an IC50 at 133 µM (homogenate incubation), while the IC50 of mitotane was 
calculated at 67 µM for the inhibitory effects on treated cells (living cell incubation). 
 
Figure 5 
Inhibition of the expression of the respiratory chain genes and proteins by mitotane.  
The steady-state levels of messenger RNA encoding for the mitochondrial DNA-encoded COX2 (A) 
and the nuclear encoded COX4 (B) were measured by RT-qPCR. The expression of both COX2 and 
COX4 transcripts was drastically reduced after exposure to 50 µM mitotane for 48 h. Results are 
expressed as the mean percentage ± SEM of 4 independent determinations performed in duplicate of 
the expression measured in untreated cells, arbitrarily set at 100%. *p<0.05, *** p<0.001 Mann 
Whitney test. 
Steady-state levels of respiratory chain whole complexes were analyzed by BN-PAGE followed by 
Western Blot with anti-GRIM 19 (a subunit of complex I), anti-70 kDa (a subunit of complex II), anti-
core2 (a subunit of complex III) and anti-COX1 (a subunit of complex IV) (C). Band intensities were 
quantified by ImageJ software revealing that mitotane reduced the steady-state of both the complex I 
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and complex IV were reduced by 45-70% but had no effect on complex II or complex III expression 
(D). Results are expressed as the mean percentage ± SEM of 4 independent determinations of the 
expression measured in untreated cells, arbitrarily set at 100%. *p<0.05, Mann Whitney test. 
 
Figure 6 
Stimulation of mitochondrial biogenesis by mitotane. Mitochondrial DNA was quantified by qPCR in 
H295R cells treated for 48 h (A) or 72 h (B) with increasing concentrations of mitotane. Higher 
mitotane concentrations (100 µM) and longer time exposure (72 h) increased mitochondrial/nuclear 
DNA ratio. Increased expression of PGC1α (peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha) in H295R cells were treated with 50 µM of mitotane for 48 h (C). Results are 
expressed as the mean percentage ± SEM of 4 independent determinations performed in duplicate of 
the expression measured in untreated cells, arbitrarily set at 100%. *p<0.05, *** p<0.001 Mann 
Whitney test. 
 
Figure 7 
Morphological changes in the mitochondrial compartment network of H295R cells treated with 50 µM 
mitotane for 48 h. Cells were fixed and immunostained with anti-COX2 antibody (green) and 
counterstained with DAPI (blue). Under mitotane exposure, the filamentous morphology of the 
mitochondrial compartment observed in vehicle-treated cells (DMSO) displayed a punctiform pattern, 
indicative of mitochondrial fragmentation. 
  
 
 
 
 
 
Table I: Mitochondrial respiratory activities 
 
  
H295R cells 
 
SW13 cells 
Conditions Vehicle 50 µM Mitotane Vehicle 50 µM Mitotane 
Citrate synthase 299 ± 22 260 ± 31 159 ± 11 135 ± 7 
Complex I 9.4  5.6 14.4 7.5 
Complex II 55 ± 8 43 ± 9 37 ± 3 32 ± 1 
Complex III 95 ± 14 86 ± 26 89 ± 6 55 ± 10* 
Complex IV 276 ± 15 153 ± 19** 283 ± 53 127 ± 37** 
CII/CS 0.28 ± 0.03 0.21± 0.03 0.26 ± 0.02 0.30 ± 0.04 
CIII/CS 0.29 ± 0.03 0.36± 0.07 0.68± 0.07 0.68± 0.10 
CIV/CS 1.05 ± 0.08      0.52± 0.02*** 0.78± 0.08   0.56± 0.01* 
 
Enzymatic activities were measured in cell homogenates with the exception of complex I, which was 
measured on purified mitochondrial fractions; values are mean ± SEM of 6-12 independent 
experiments, expressed as nmol/min/mg prot. Ratio between Complex II or Complex III or 
ComplexIV/Citrate synthase (CS) activities are also presented.* p< 0.05 **p< 0.01 ***p< 0.001 with 
non-parametric Mann Whitney test. 
 
Supplemental Table  
Primer sequences of genes analyzed by qRT-PCR 
Gene  Size Sense sequences   Antisense sequences  
18S  71 pb GTGCATGGCCGTTCTTAGTTG  CATGCCAGAGTCTCGTTCGTT  
COX 2  194 pb TACGGCGGACTAATCTTCAA  CCGGGAATTGCATCTGTTTT  
COX 4  143 pb TGGATGAGAAAGTCGAGTTG  CTTCTGCCACATGATAACGA  
StAR 121 pb GCCACAGACTTCGGGAACAT AGTAGCCACGTAAGTTTGGTCTTAGAG 
Cyp11B1  99 pb GGAGACACTAACCCAAGAGGACAT  ACGTGATTAGTTGATGGCTCTGAA  
Cyp11B2  144 pb AGGCCCCTGTGGTCACTTATC  CAACACTCGCTGCTTGAACAA  
PGC1α  159 pb AAGAGCGCCGTGTGATTTAT  TCACAGGTATAACGGTAGGT  
 
